&nbsp;

2019_Ontario_Medical_Physics_Residency_Program_CAMPEP_Statistics_Final

Jun 2020

Document

2018pebc_conflict_of_interest_policy_2018_May

Jul 2020

Regimen

MPC+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Curative

Funding:

ODB - General Benefit

procarbazine

Drugs Used:

riTUXimab (Unfunded),

Quick Link(s):

Regimen Monograph

Dec 2020

Regimen

MFOLFOX6+TRAS

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2023

Manipulation sécuritaire des médicaments contre le cancer et des fluides corporels à la maison

Document

metis-brochure-thumbnail.jpg

Apr 2021

Document

metis-fr-brochure-thumbnail.jpg

May 2021

Document

2020Ontario Medical Physics Residency Program CAMPEP Statistics - Compiled.pdf

Jun 2021

Regimen

MPV+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade

Intent: Curative

Drugs Used:

riTUXimab (Unfunded),

Quick Link(s):

Regimen Monograph

Jun 2022

Guidelines and Advice

Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and the American Society of Clinical Oncology Joint Guideline

Status: Current
ID: GL 1-23-A

Jul 2021

Regimen

MFOLFOX6+NIVL

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab - First-line Treatment of Advanced Gastric, Esophageal, and Esophagogastric Junction Adenocarcinoma

Drugs Used: